ScholarIQanswers from OpenAlex
Dana-Farber/Harvard Cancer Center
InstitutionResearch output, impact & collaborations
Dana-Farber/Harvard Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Dana-Farber/Harvard Cancer Center?
ScholarIQrecord summary
Dana-Farber/Harvard Cancer Center is a research organisation in Boston, US. OpenAlex records 15,153 works and 1,664,646 citations for it. 1,678 researchers list it as their most recent affiliation.
How many works does Dana-Farber/Harvard Cancer Center have?
ScholarIQindexed works
Dana-Farber/Harvard Cancer Center has 15,153 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dana-Farber/Harvard Cancer Center have?
ScholarIQcitation count
Dana-Farber/Harvard Cancer Center has 1,664,646 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Dana-Farber/Harvard Cancer Center?
ScholarIQresearcher count
Dana-Farber/Harvard Cancer Center has 1,678 researchers in the ScholarIQ index.
What is the average h-index at Dana-Farber/Harvard Cancer Center?
ScholarIQavg h-index
Dana-Farber/Harvard Cancer Center has an average h-index of 73.8 in OpenAlex.
What is the ROR of Dana-Farber/Harvard Cancer Center?
ScholarIQror
The ROR for Dana-Farber/Harvard Cancer Center is on the source record.
What is the OpenAlex record for Dana-Farber/Harvard Cancer Center?
ScholarIQopenalex
The OpenAlex for Dana-Farber/Harvard Cancer Center is on the source record.
Who are the most-cited researchers behind Dana-Farber/Harvard Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Dana-Farber/Harvard Cancer Center?
ScholarIQmost cited works
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan, Mark L. Bernstein, Pancras C.W. Hogendoorn, Mark Krailo, Richard Görlick, Katherine A. Janeway, Fiona C. Ingleby, Jakob Anninga, Imre Antal, Carola Arndt, Ken Brown, Trude Butterfaß‐Bahloul, Gabriele Calaminus, Michael Capra, Catharina Dhooge, Mikael Eriksson, Adrienne M. Flanagan, Godehard Friedel, Mark C. Gebhardt, Hans Gelderblom, Robert E. Goldsby, Holcombe E. Grier, R. J. Grimer, Douglas S. Hawkins, Stefanie Hecker‐Nolting, Kirsten Sundby Hall, Michael S. Isakoff, Gordana Jovic, Thomas Kühne, Leo Kager, Thekla von Kalle, Edita Kabíčková, Susanna Lang, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Regine Mayer‐Steinacker, Paul A. Meyers, Raj Nagarajan, R. Lor Randall, Peter Reichardt, Marleen Renard, Catherine Rechnitzer, Cindy L. Schwartz, Sandra J. Strauss, Lisa A. Teot, Beate Timmermann, Matthew R. Sydes, Neyssa Marina
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura E. Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina, Sigbjørn Smeland, Stefan Bielack, Mark L. Bernstein, Gordana Jovic, Mark Krailo, Jane Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken Brown, Trude Butterfaß‐Bahloul, Gabriele Calaminus, Heike E. Daldrup‐Link, Mikael Eriksson, Mark C. Gebhardt, Hans Gelderblom, Joachim Gerß, Robert E. Goldsby, Allen M. Goorin, Richard Görlick, Holcombe E. Grier, Juliet Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S. Hawkins, K. Helmke, Pancras C.W. Hogendoorn, Michael S. Isakoff, Katherine A. Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Paul A. Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Pápai, R. Lor Randall, Peter Reichardt, Marleen Renard, Akmal Safwat, Cindy L. Schwartz, Michaël C.G. Stevens, Sandra J. Strauss, Lisa A. Teot, Mathias Werner, Matthew R. Sydes, Jeremy Whelan
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Noritaka Tanaka, Jessica J. Lin, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, Katerina A. Fella, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran
Recognizing the reagent microbiome
Marcus C. de Goffau, Susanne Lager, Susannah J. Salter, Josef Wagner, Andreas Kronbichler, D. Stephen Charnock‐Jones, Sharon J. Peacock, Gordon C. S. Smith, Julian Parkhill
How much of the research on Dana-Farber/Harvard Cancer Center is open access?
ScholarIQopen access share
89%OPEN ACCESS